The clinical study, conducted at the Reproductive Medicine Center (RMC) in Malmö, demonstrated a statistically significant correlation between the JUNO Score — which measures sperm binding to the JUNO receptor — and fertilization rate in IVF. Notably, 22% of the men in the study had a low JUNO Score, despite having normal sperm parameters, highlighting the limitations of conventional semen analysis. The findings, announced in June, underscore the unique diagnostic value of JUNO-Checked in assessing a critical step in fertilization that current methods cannot evaluate. A peer-reviewed article detailing the results is in preparation.

In parallel, the Company’s T05 warrants were fully subscribed during the June subscription period which strengthen Spermosens’ financial position and enable continued technology optimization and strategic business development.

With positive clinical results and an improved financial foundation, Spermosens is accelerating its efforts to secure strategic partners in Europe, the United States and Japan. Following the announcement of the clinical results, the Company has seen growing interest in its technology and is actively engaged in discussions with several potential partners across key markets.

At the same time, Spermosens has initiated optimization of the JUNO-Checked system to meet commercial demands. This work aims to bring the system closer to a commercial launch in collaboration with established partners. The goal is to deliver accurate and efficient measurement of sperm cells’ ability to bind to the egg with higher throughput, faster analysis time and adapted for routine laboratory practice.

The ongoing optimization is expected to result in a diagnostic tool with the potential to transform how sperm quality is assessed. JUNO-Checked may enable more effective IVF treatments, improved selection of sperm donors, and potentially a new way to evaluate when a man is most fertile.

Next major milestones in the Company’s development include finalization of the third-generation JUNO-Checked system, clinical validation of this next version, and the signing of partnership agreements to enable commercialization.

Dr. Tore Duvold, CEO of Spermosens, comments: "We are pleased with the strong clinical results, our strengthened financial position, and the growing interest in our technology. These factors give us confidence in our ability to advance JUNO-Checked towards commercialization in collaboration with established partners."

For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com